CurrentCignaPolicy IP0066

Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy — Coverage Criteria

Defines medical necessity, authorization, coding, and coverage limits for viltolarsen (Viltepso) intravenous infusion for patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyViltolarsen (Viltepso) for Duchenne Muscular Dystrophy — Coverage Criteria

Policy CodePolicy IP0066

Change TypeAdministrative update (no material clinical or coverage changes)

Effective DateDec 15, 2024

Next Review Date

Key ActionObtain prior authorization; initial approval may be granted for up to 6 months with reauthorization up to 6 months when criteria are met.

SourceLink

POLICY UPDATE CHANGES

Updated review date, disclaimer, refreshed background and references, addition of change history.

up to 6 moInitial authorization duration

up to 6 moReauthorization duration

J1427HCPCS code

<10 yrsAge limit

6MWTAmbulatory requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Viltolarsen (Viltepso)

inv-01: Initial medical necessity — Covered when ALL of the following are met:

Covered when ALL of the following are met:

DMD diagnosis and eligibility: Individual has documented diagnosis of Duchenne muscular dystrophy (DMD); confirmed DMD gene mutation amenable to exon 53 skipping; less than 10 years of age at start of therapy; ambulatory and baseline 6-minute walk test (6MWT) results submitted; medication prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association (MDA) clinic.

inv-02: Reauthorization — Covered for continuation when ALL of the following are met:

Covered for continuation when ALL of the following are met:

Reauthorization: Initial medical necessity criteria continue to be met AND documentation of beneficial response, including continued ability to walk.

Concurrent administration of viltolarsen with other exon-skipping dystrophin therapies is not supported. Concurrent use with other exon-skipping DMD agents (for example, Amondys 45, Exondys 51, or Vyondys 53) is listed as a condition not covered because there is no clinical evidence to support combining exon-skipping agents for treatment of Duchenne muscular dystrophy.

Use of viltolarsen for any indication other than treatment of Duchenne muscular dystrophy in patients with a confirmed DMD gene mutation amenable to exon 53 skipping is considered not medically necessary / experimental or investigational. This exclusion applies to all other uses not specifically listed as covered.

Coding and Related Criteria

Considered Medically Necessary when criteria metHCPCSCovered

J1427

Injection, viltolarsen, 10 mg

inv-06: Age at therapy start — less than 10 years

Age requirement at therapy startLess than 10 years of age at start of therapy

Documentation neededAge must be documented in authorization records for initial approval

Relevance to reauthorizationReauthorization requires continued meeting of initial criteria including age at therapy start

inv-07: Baseline functional test — submit baseline 6-minute walk test (6MWT) results

Required baseline assessmentSubmit baseline 6-minute walk test (6MWT) results prior to initiation

Ambulatory statusMember must be ambulatory at baseline to perform 6MWT

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required. Initial approvals are for up to 6 months; reauthorization may be granted for up to 6 months when continuation criteria are met.

Initial approval duration: up to 6 months
Reauthorization approval duration: up to 6 months

Step Therapy

Step therapy / Guideline Context

No step therapy is specified for viltolarsen. Clinical guideline context: DMD management follows DMD Care Considerations and requires genetic testing to confirm mutations; exon‑skipping therapies (including exon 53 agents) are mutation‑specific and not broadly addressed in current guideline recommendations.

Background

Viltepso (viltolarsen) is an antisense oligonucleotide designed to induce exon 53 skipping in dystrophin pre-mRNA for patients with Duchenne muscular dystrophy whose genetic mutation is amenable to exon 53 exclusion. The policy notes that concurrent use with other exon-skipping agents is not supported, reflecting limited clinical evidence for combined exon-skipping therapies.

Definitions

inv-13: Exon 53 skipping — definition of the exon-skipping mechanism

Mechanism descriptionAntisense oligonucleotide binds to exon 53 of dystrophin pre-mRNA to exclude this exon during mRNA processing, restoring the mRNA reading frame in certain mutations

Therapeutic intentRestored reading frame produces a shortened but partially functional dystrophin protein

Target populationApplicable to patients with DMD gene mutations amenable to exon 53 skipping (approximately 8–10% of DMD patients)

inv-14: 6MWT — definition of the 6-minute walk test as baseline ambulatory functional assessment

Test definition6-minute walk test (6MWT): a baseline ambulatory functional assessment required prior to initiation

Requirement link

Revision History

2024-12-15Administrative updateLatest

Updated review date, disclaimer, refreshed background and references, and addition of change history; no clinical, coverage, or coding changes specified.

Policy Summary

PayerCigna

PolicyViltolarsen (Viltepso) for Duchenne Muscular Dystrophy — Coverage Criteria

Policy CodePolicy IP0066

Change TypeAdministrative update (no material clinical or coverage changes)

Effective DateDec 15, 2024

Next Review Date

Key ActionObtain prior authorization; initial approval may be granted for up to 6 months with reauthorization up to 6 months when criteria are met.

SourceLink

On This Page

Use in authorizationBaseline 6MWT results are part of required documentation for initial authorization

Documentation Required

Required Documentation for Initial Authorization

Documentation must include confirmation of DMD diagnosis, genetic test demonstrating a DMD gene mutation amenable to exon 53 skipping, age at therapy initiation, baseline ambulatory status, and baseline functional data (including 6‑minute walk test results). Medication should be prescribed by or in consultation with a neurologist, neuromuscular specialist, or an MDA clinic.

Documented diagnosis of Duchenne muscular dystrophy (DMD)
Genetic test confirming exon 53‑amenable DMD mutation
Age < 10 years at therapy start
Baseline ambulatory status (must be able to walk)
Baseline 6 minute walk test (6MWT) results
Prescribing clinician: neurologist, neuromuscular specialist, or MDA clinic

Denial Risk

Experimental / Investigational Exclusions

Use of viltolarsen for indications other than DMD with an exon 53‑amenable mutation or concurrent use with other exon‑skipping agents (e.g., Amondys 45, Exondys 51, Vyondys 53) is considered experimental, investigational, or unproven and is not covered.

Concurrent use with other exon‑skipping DMD agents is not covered

Member must be able to walk and submit 6MWT results as part of initial medical necessity criteria

PurposeProvides objective measure of ambulatory function to document baseline and assess response